Cancer: Symptoms, Types, Stages & Integrative Treatment NYC

Cancer

Cancer: Types, Symptoms, Stages & Integrative Treatment in NYC

Cancer arises when accumulated DNA mutations strip cells of their normal growth controls, enabling them to proliferate without restraint and invade surrounding tissue. For millions of patients, the cancer journey is not only about eradicating tumours—it is about rebuilding the biological terrain, restoring immune function, and reclaiming quality of life at every stage.

1 in 2

Men will develop cancer in their lifetime (US)

1 in 3

Women will develop cancer in their lifetime (US)

100+

Distinct cancer types across all organ systems

18M+

New cancer diagnoses globally each year (WHO)

Medically reviewed by Dr. Rashmi Gulati, MD — Medical Director, Patients Medical.

Board-certified integrative medicine physician.

Clinical Definition

Cancer is a group of diseases characterised by the uncontrolled proliferation of abnormal cells that have acquired mutations in DNA repair, apoptosis, and cell-cycle regulation pathways. These malignant cells invade surrounding tissues and can metastasise to distant organs via the bloodstream or lymphatic system. Cancer encompasses more than 100 distinct disease types, unified by the hallmarks of self-sufficiency in growth signals, evasion of growth suppressors, resistance to programmed cell death, limitless replicative potential, sustained angiogenesis, and tissue invasion and metastasis.

Key Symptoms

Unexplained, sustained weight loss
Persistent fatigue unrelieved by rest
Unexplained pain in any body region
A new lump or thickening anywhere
Unusual bleeding or discharge
Persistent cough or hoarseness

Primary Causes

Accumulated somatic DNA mutations
Chronic inflammation (NF-kB activation)
Carcinogen and toxin exposure
Viral oncogenes (HPV, EBV, HBV)
Immune surveillance failure
Mitochondrial dysfunction

Treatment Approach

High-dose IV vitamin C therapy
Mistletoe (Iscador) immune support
Metabolic and nutritional optimisation
Detoxification protocols
NK cell immune activation
Anti-inflammatory dietary therapy

What is Cancer?

Cancer is not a single disease—it is an umbrella term encompassing more than 100 distinct malignancies that share one defining characteristic: cells that have lost the biological constraints governing normal growth, division, and death. In a healthy body, an intricate molecular machinery controls every aspect of the cell cycle. Proto-oncogenes act as accelerators, stimulating cell growth when needed; tumour-suppressor genes act as brakes, halting the cycle when damage is detected; and apoptosis pathways function as a self-destruct mechanism for cells that are too abnormal to repair. Cancer begins when mutations disable enough of these safeguards that a single cell becomes the founder of an expanding, invasive clone.

The biological mechanism underlying cancer development is best understood through the “hallmarks of cancer” framework, first articulated by Douglas Hanahan and Robert Weinberg in a landmark paper in 2000 and updated in 2011. These hallmarks describe the capabilities that normal cells must acquire to become malignant: self-sufficiency in growth signals (often through mutated oncogenes like RAS or MYC); insensitivity to anti-growth signals (through loss of tumour suppressors like TP53 or RB1); evasion of programmed cell death (apoptosis); limitless replicative potential (through telomerase activation); sustained angiogenesis (the formation of new blood vessels to feed the tumour); and the ability to invade local tissue and metastasise. More recent expansions to this framework add immune evasion, reprogrammed energy metabolism (the Warburg effect, whereby cancer cells preferentially consume glucose via glycolysis even in oxygen-rich environments), and chronic tumour-promoting inflammation as additional hallmarks.

From a functional medicine perspective, conventional oncology’s focus on tumour biology is necessary but incomplete. Functional medicine asks a deeper question: what made the terrain—the body’s overall biological environment—hospitable to cancer in the first place? Factors such as chronic low-grade inflammation, impaired immune surveillance, mitochondrial dysfunction, nutritional deficiencies, elevated insulin and IGF-1 signalling, gut dysbiosis, environmental toxin accumulation, and chronic psychological stress all create conditions that favour tumour initiation and progression. Addressing these upstream drivers does not replace conventional oncology; it works synergistically with it to optimise treatment tolerance, reduce recurrence risk, and restore long-term health.

Cancer collectively affects approximately one in two men and one in three women in the United States at some point in their lifetime, according to the National Cancer Institute. Globally, the World Health Organisation reports more than 18 million new cases and nearly 10 million cancer-related deaths annually, making it the second leading cause of mortality worldwide after cardiovascular disease. Despite these statistics, it is critical to acknowledge that survival rates have improved dramatically over the past three decades—a testament to both advances in early detection and the expanding therapeutic arsenal, including targeted therapies, immunotherapy, and integrative supportive care.

DNA & Tumour Suppressor Genes

Genes such as TP53 (found mutated in over 50% of human cancers), BRCA1, and RB1 act as guardians of the genome—halting cell division when DNA damage is detected or triggering apoptosis when repair is impossible. Their loss-of-function is central to most cancers.

The Immune System & NK Cells

Natural killer (NK) cells, cytotoxic T-lymphocytes, and macrophages continuously patrol for and destroy pre-malignant cells. Immune surveillance failure—whether from nutrient deficiency, chronic stress, or tumour-mediated immune suppression—is a prerequisite for cancer escape.

Mitochondria & Energy Metabolism

Cancer cells preferentially ferment glucose to lactate even in the presence of oxygen (the Warburg effect), generating a distinctive metabolic signature. Mitochondrial dysfunction—driven by toxins, nutrient deficiency, and chronic oxidative stress—is increasingly recognised as a driver of malignant transformation.

Signs & Symptoms of Cancer: A Complete Overview

Cancer symptoms are extraordinarily diverse because the disease can originate in virtually any tissue in the body; the symptoms you experience depend on the organ of origin, the stage, and the biological effects of tumour-derived substances on distant tissues—a phenomenon known as paraneoplastic syndrome.

Energy & Systemic

Profound, unexplained fatigue

Caused by anaemia (from erythropoietin suppression by pro-inflammatory cytokines), increased metabolic demand of tumour cells, and disrupted mitochondrial energy production.

Unintentional weight loss

More than 5% of body weight over 6–12 months results from tumour metabolic competition for glucose and protein catabolism via cancer-associated cachexia.

Persistent low-grade fever

Tumour cells and immune effectors release pyrogenic cytokines (IL-1β, IL-6, TNF-α), chronically elevating body temperature—a common sign in lymphomas and leukaemias.

Night sweats

Autonomic dysregulation and cytokine-mediated hypothalamic stimulation produce drenching nocturnal perspiration, classically associated with lymphoma.

General malaise and loss of appetite

Elevated leptin resistance and circulating inflammatory mediators suppress appetite centres in the hypothalamus, contributing to the anorexia-cachexia syndrome.

Neurological & Cognitive

Cognitive impairment ("chemo brain")

Even before treatment, inflammatory cytokines and tumour-derived exosomes can cross the blood-brain barrier, impairing working memory, attention, and processing speed.

Headaches and seizures

Primary or metastatic brain tumours exert mechanical pressure on neural tissue and disrupt electrical signalling, presenting as persistent headaches or new-onset seizures.

Peripheral neuropathy

Paraneoplastic neuropathy (particularly in lung, ovarian, and breast cancers) results from autoantibodies targeting neural antigens, causing tingling, numbness, and weakness in the extremities.

Personality or mood changes

Frontal lobe tumours or limbic encephalitis can produce profound personality alterations, depression, and anxiety as initial manifestations of malignancy.

Vision changes or diplopia

Orbital or posterior fossa tumours, and paraneoplastic retinopathy, can disrupt vision important to evaluate when unexplained and progressive.

Physical & Structural

A new lump or thickening

A persistent, painless mass in the breast, groin, neck, or elsewhere warrants urgent evaluation, as it may represent a primary tumour or lymph node metastasis.

Unusual bleeding or discharge

Post-menopausal vaginal bleeding, blood in urine or stool, or haemoptysis (coughing blood) are classic red-flag symptoms requiring prompt investigation for endometrial, colorectal, bladder, or lung cancer respectively.

Persistent sores that do not heal

Non-healing ulcers, particularly in the oral cavity, skin, or genitals, may represent squamous cell carcinoma or melanoma.

Unexplained pain

Bone pain from metastases (particularly in prostate, breast, lung, and kidney cancers) or abdominal pain from visceral tumours may be an early clue, especially if persistent and progressive.

Skin changes

Jaundice, pruritus, hyperpigmentation (acanthosis nigricans), sudden dermatomyositis, or a new pigmented lesion with irregular borders all carry oncological significance.

Digestive & Respiratory

Persistent cough or hoarseness

A cough lasting more than three weeks, particularly with haemoptysis or a new voice change, is a key red-flag symptom for lung, laryngeal, or thyroid cancer.

Difficulty swallowing (dysphagia)

Progressive difficulty swallowing solids, then liquids, is a hallmark presentation of oesophageal cancer and warrants urgent endoscopic evaluation.

Changes in bowel habits

New-onset constipation, diarrhoea, or alternating bowel habits persisting for more than four weeks—especially with rectal bleeding—are key screening indicators for colorectal cancer.

Abdominal bloating and early satiety

Particularly in women over 50, persistent bloating accompanied by pelvic pressure and urinary urgency is a triad that should prompt evaluation for ovarian cancer.

Indigestion or nausea

Persistent dyspepsia unresponsive to standard therapy, particularly when associated with weight loss, may indicate gastric cancer.

The Four Stages of Cancer: What Staging Means for Treatment

Cancer staging is the universal language of oncology—it tells your clinical team how extensively the cancer has spread and is the single most important factor determining prognosis and treatment strategy. The TNM classification system, used by the American Joint Committee on Cancer (AJCC), assigns a stage based on Tumour size (T), lymph Node involvement (N), and the presence of distant Metastasis (M). Stages I through IV reflect increasing spread; understanding your stage is essential for making informed treatment decisions and for contextualising integrative support goals.

01 Localised Cancer

Tumour confined to organ of origin

The cancer is small, localised, and has not spread to nearby lymph nodes or other organs. Surgery alone, or surgery combined with radiation, is often curative at this stage, and five-year survival rates frequently exceed 90% for many cancer types. Integrative support at this stage focuses on optimising surgical recovery, reducing recurrence risk, and building long-term immune resilience.

02 Regional Growth

Larger tumour, possible node involvement

The tumour has grown larger and may have spread to adjacent tissues or nearby lymph nodes, but has not reached distant organs. Treatment typically combines surgery with adjuvant chemotherapy or radiation. Functional medicine support focuses on maintaining nutritional status during treatment, supporting immune function, managing inflammation, and reducing treatment toxicity through targeted nutraceutical protocols.

03 Extensive Regional Spread

Significant lymph node involvement

Cancer has spread extensively to regional lymph nodes and possibly to adjacent organs. Multi-modal treatment—surgery, chemotherapy, radiation, and potentially immunotherapy or targeted therapy—is standard at this stage. Integrative support becomes particularly important here: high-dose IV vitamin C, mistletoe therapy, mitochondrial support, and anti-inflammatory protocols are used to improve treatment tolerance and quality of life.

04 Metastatic Disease

Distant organ metastases present

Cancer has metastasised to distant organs such as the liver, lungs, bones, or brain. While most stage IV cancers are considered incurable by conventional standards, modern systemic therapies—including checkpoint inhibitors, targeted agents, and antibody-drug conjugates—have transformed many into chronic manageable conditions. Integrative medicine at this stage prioritises quality of life, immune optimisation, and supporting the efficacy and tolerability of ongoing systemic therapy.

Causes & Risk Factors for Cancer: A Functional Medicine View

Most cancers do not arise from a single cause—they are the cumulative result of multiple interacting biological insults occurring over years or decades. Think of cancer development as a tipping point: each risk factor below contributes to a progressive erosion of the body’s cellular safeguards. Understanding your specific constellation of exposures and vulnerabilities is the foundation of personalised cancer prevention and integrative support.

01

Accumulated somatic DNA mutations

Random errors in DNA replication, occurring at a rate of approximately one per ten billion base pairs per replication cycle, accumulate over a lifetime; when mutations strike tumour-suppressor genes or proto-oncogenes, the cancer process begins.

02

Tobacco and tobacco smoke carcinogens

Tobacco smoke contains more than 70 known carcinogens, including polycyclic aromatic hydrocarbons and nitrosamines, responsible for approximately 30% of all cancer deaths and strongly linked to lung, oral, bladder, and pancreatic cancers.

03

Chronic inflammation (NF-kB pathway activation)

Sustained activation of the transcription factor NF-kB—driven by obesity, poor diet, gut dysbiosis, or chronic infection—upregulates pro-survival signals in mutant cells, suppresses apoptosis, and creates a mutagenic microenvironment rich in reactive oxygen species.

04

Oncogenic viral infections

Human papillomavirus (HPV) types 16 and 18 are responsible for virtually all cervical cancers and a growing proportion of head and neck cancers; Epstein-Barr virus (EBV) is causally linked to Burkitt’s lymphoma and nasopharyngeal carcinoma; hepatitis B and C viruses drive the majority of hepatocellular carcinoma cases worldwide.

05

Ionising and UV radiation

Ultraviolet B radiation from sun exposure directly damages keratinocyte DNA through cyclobutane pyrimidine dimer formation, driving melanoma and non-melanoma skin cancers; ionising radiation from X-rays and radon gas exposure increases leukaemia and lung cancer risk.

06

Hereditary germline mutations

Inherited mutations in BRCA1/2 confer up to an 80% lifetime risk of breast cancer; mutations in MLH1, MSH2 (Lynch syndrome) confer high colorectal and endometrial cancer risk; BRCA2, PALB2, and APC mutations underlie familial pancreatic, prostate, and colorectal cancers respectively.

07

Obesity and metabolic syndrome

Adipose tissue functions as an endocrine organ, secreting excess oestrogen, insulin-like growth factor-1 (IGF-1), leptin, and inflammatory adipokines that drive proliferation in breast, endometrial, colorectal, and oesophageal cancers; obesity is now linked to at least 13 cancer types.

08

Alcohol consumption

Ethanol metabolism generates acetaldehyde, a potent carcinogen that forms DNA adducts; alcohol also depletes folate, elevates oestrogen, and suppresses immune function, increasing risk for cancers of the mouth, throat, oesophagus, liver, colon, and breast.

09

Environmental and occupational carcinogens

Asbestos (mesothelioma, lung cancer), benzene (leukaemia), arsenic (skin, lung, bladder), formaldehyde (nasopharyngeal cancer), and pesticides including glyphosate (non-Hodgkin’s lymphoma) all carry documented causal relationships with specific malignancies.

10

Gut microbiome dysbiosis

An imbalanced gut microbiome generates pro-carcinogenic metabolites—including deoxycholic acid from Fusobacterium nucleatum and secondary bile acids—and impairs the gut immune barrier, creating systemic low-grade endotoxemia that drives NF-kB-mediated cancer promotion.

11

Mitochondrial dysfunction and oxidative stress

Impaired mitochondrial respiratory chain function—from nutrient deficiencies (CoQ10, magnesium), toxin exposure, or ageing—generates excess reactive oxygen species that oxidise DNA and lipid membranes, driving mutagenesis and the metabolic reprogramming characteristic of cancer cells.

12

Chronic psychological stress and neuroendocrine dysregulation

Sustained hypothalamic-pituitary-adrenal axis activation elevates cortisol and catecholamines that suppress NK cell cytotoxicity, downregulate tumour-suppressor gene expression, and promote angiogenesis and metastasis through beta-adrenergic signalling pathways in tumour cells.

Cancer vs. Related Conditions: Key Diagnostic Distinctions

Several serious conditions share overlapping symptoms with cancer—including unexplained fatigue, weight loss, lymphadenopathy, and anaemia—making accurate differential diagnosis essential. The following comparison helps clarify the distinguishing features of cancer versus conditions frequently encountered in functional medicine practice.

Feature	Cancer (Malignant Neoplasm)	Chronic Fatigue Syndrome	Autoimmune Disease	Lymphoma vs Reactive Lymphadenopathy
Key biomarker	Elevated tumour markers (CEA, CA-125, PSA); ctDNA; elevated LDH	Impaired NK cell function; elevated IL-6; no tumour marker elevation	Elevated ANA, anti-dsDNA, RF, ANCA; complement consumption	Elevated LDH, beta-2 microglobulin; abnormal lymphocyte morphology on biopsy
Best diagnostic test	Tissue biopsy + histopathology; PET-CT scan; liquid biopsy (ctDNA)	Clinical criteria (Fukuda or IOM); NK cell activity assay; no definitive biomarker	Specific antibody panel; inflammatory markers; organ-specific biopsy	Excisional lymph node biopsy + flow cytometry; bone marrow biopsy
Hallmark symptom	Progressive unintentional weight loss, new palpable mass, haemoptysis or rectal bleeding	Post-exertional malaise lasting >24 hours; no physical findings; normal imaging	Symmetrical joint inflammation, butterfly rash, or organ-specific symptoms with positive serology	Painless, firm, rubbery lymph node enlargement persisting >4 weeks without infection
Blood test detection	Elevated ESR, CRP, LDH, ferritin; anaemia; tumour markers; CBC abnormalities	Usually unremarkable standard CBC and metabolic panel; functional testing shows immune anomalies	Positive autoantibodies; elevated inflammatory markers; complement low; organ-specific panels	Elevated LDH and beta-2 microglobulin; abnormal peripheral blood smear; elevated ESR
Treatment approach	Surgery, chemotherapy, radiation, immunotherapy, targeted therapy + integrative oncology	Pacing, sleep restoration, neuroendocrine support, immune modulation, mitochondrial therapy	Disease-modifying antirheumatic drugs (DMARDs), biologics, corticosteroids + functional medicine terrain work	Chemotherapy, monoclonal antibodies (rituximab), autologous stem cell transplant + integrative support
Overlap with cancer risk	—	Some evidence of impaired cancer immune surveillance due to NK cell dysfunction	Autoimmune conditions (RA, SLE, Sjögren’s, IBD) carry elevated lymphoma risk	Reactive lymphadenopathy can mask early lymphoma—differentiation requires biopsy

Important clinical note: The fatigue, weight loss, and lymph node enlargement seen in chronic fatigue syndrome, autoimmune disease, and lymphoma can all mimic early cancer. Any symptom cluster that does not resolve within 4–6 weeks, or that is accompanied by unintentional weight loss, should be evaluated with appropriate imaging and laboratory testing before attributing to a non-malignant diagnosis.

Integrative Oncology: Is There a Role Alongside Conventional Cancer Treatment?

Cancer is unequivocally recognised by all medical traditions as a serious, life-threatening disease requiring evidence-based treatment. However, a substantive and evidence-growing debate exists about the role of integrative medicine—specifically whether nutritional, immunological, and lifestyle interventions used alongside conventional oncology provide measurable clinical benefit or potentially interfere with treatment. Here is where the evidence and the perspectives diverge:

01 Conventional Oncology's Cautions

Some antioxidant supplements (e.g. high-dose vitamin E, beta-carotene) may interfere with the oxidative mechanism of specific chemotherapy agents and radiation therapy
St John's Wort and other herbal agents induce CYP3A4 liver enzymes, potentially reducing serum levels of targeted therapies such as imatinib and irinotecan
Quality control for many supplements is inconsistent, making reliable dosing and purity claims difficult to verify
Patients who pursue alternative therapies as a replacement for proven conventional treatment have demonstrably worse outcomes in multiple studies
The evidence base for many integrative modalities remains primarily observational, with limited randomised controlled trial data for efficacy claims

02 Integrative Medicine's Perspective

High-dose intravenous vitamin C has demonstrated safety when used as an adjunct (not a replacement) to chemotherapy in multiple Phase I and Phase II trials, including studies published in Science Translational Medicine
Mistletoe extract (Viscum album) is backed by over 100 clinical studies and is used in European oncology centres to improve quality of life, NK cell activity, and chemotherapy tolerance
Optimising vitamin D3, omega-3 index, and selenium is low-risk, low-cost, and associated with improved prognosis across multiple cancer types in meta-analyses
Gut microbiome composition is now established to predict response to checkpoint inhibitor immunotherapy, making gut-directed interventions clinically relevant
Addressing sleep, stress, nutrition, and exercise are universally endorsed by ASCO and NCCN guidelines as components of comprehensive cancer care

Patients Medical Position: At Patients Medical, we are unequivocal that conventional oncology—surgery, chemotherapy, radiation, targeted therapy, and immunotherapy—is the primary treatment framework for cancer. We practice integrative oncology: evidence-informed supportive care that works alongside your oncologist, never as a replacement for proven treatment. Every integrative protocol we implement is reviewed for drug interactions, screened against your specific treatment plan, and communicated to your oncology team. We do not offer false hope or unproven cures. We offer measurable optimisation of the biological terrain—and that is a meaningful contribution to the cancer journey.

How We Evaluate Cancer Patients at Patients Medical NYC

At Patients Medical, our functional evaluation of cancer patients goes far beyond the standard oncology panel. We assess the entire biological terrain—immune capacity, inflammatory burden, nutritional status, oxidative stress, hormonal milieu, and gut microbiome—to understand what allowed cancer to arise and what is needed to optimise treatment outcomes and long-term resilience.

01 Tumour Markers Panel (CEA, CA-125, PSA, AFP, CA 19-9)

Specific tumour-associated glycoproteins secreted by malignant cells serve as both diagnostic and monitoring markers. Carcinoembryonic antigen (CEA) is elevated in colorectal, lung, and breast cancers; CA-125 is a primary marker for ovarian cancer; PSA (prostate-specific antigen) is monitored in prostate cancer; alpha-fetoprotein (AFP) is the primary hepatocellular carcinoma marker; CA 19-9 monitors pancreatic cancer. Baseline values and trend over time are both clinically meaningful.

02 Liquid Biopsy — Circulating Tumour DNA (ctDNA)

Circulating tumour DNA fragments shed by cancer cells into the bloodstream carry the genetic signature of the tumour, allowing detection of oncogenic mutations (KRAS, EGFR, TP53, PIK3CA), monitoring of treatment response, and early identification of resistance mutations—all from a simple blood draw. This technology, offered through platforms such as Guardant360 and FoundationOne Liquid CDx, is transforming early detection and personalised treatment selection.

03 Natural Killer (NK) Cell Activity Assay

This specialised functional immunology test measures the cytotoxic capacity of your NK cells—the immune system’s first line of defence against malignant cells. Unlike standard lymphocyte counts, which only measure cell numbers, the NK activity assay measures actual killing function. Impaired NK cell activity is a key indicator of immune surveillance failure and predicts higher cancer recurrence risk. This test guides targeted immune-modulatory interventions including beta-glucan therapy, mistletoe, and IV vitamin C protocols.

04 Comprehensive Oxidative Stress Panel (8-OHdG, Glutathione, SOD)

8-hydroxy-2-deoxyguanosine (8-OHdG) is a validated biomarker of oxidative DNA damage—elevated in nearly all cancer types and a measure of ongoing mutagenic pressure. Glutathione peroxidase activity and erythrocyte superoxide dismutase (SOD) quantify antioxidant reserve. Together, these markers reveal the degree of oxidative burden driving genomic instability and guide targeted antioxidant replenishment strategies that support rather than interfere with conventional treatment.

05 Comprehensive Nutritional, Hormonal & Inflammatory Panel

A full functional assessment includes serum 25-OH vitamin D3 (optimal oncology range 60–80 ng/mL), omega-3 index, magnesium RBC, zinc plasma, selenium, CoQ10, and B12/folate—all nutrients critical for DNA repair and immune function that are routinely depleted by cancer treatments. High-sensitivity CRP, IL-6, TNF-α, NF-kB activity, homocysteine, insulin, and fasting glucose assess the inflammatory and metabolic microenvironment. DUTCH comprehensive hormone metabolite testing evaluates oestrogen detoxification pathways—critical in hormone-sensitive cancers.

Does This Sound Like You?

Check all that apply to your current experience:

Unexplained fatigue that does not improve with rest
Unintentional weight loss of more than 5 lbs
A new lump, mass, or thickening anywhere
Persistent cough, hoarseness, or shortness of breath
Unusual bleeding, discharge, or non-healing sore
Changes in bowel or bladder habits lasting >4 weeks
Persistent pain with no clear musculoskeletal cause
Night sweats and low-grade fevers without infection
Difficulty swallowing or persistent indigestion

Cancer Treatment at Patients Medical NYC: A Root-Cause Integrative Approach

At Patients Medical, our integrative oncology programme is built on a fundamental conviction: that the most effective cancer care combines the precision of conventional medicine with the biological intelligence of functional medicine. We do not offer unproven alternatives—we offer evidence-informed, deeply personalised terrain optimisation that works synergistically with your oncology team’s treatment plan to improve outcomes, reduce side effects, and rebuild long-term health.

High-Dose Intravenous Vitamin C Therapy

At pharmacological doses (25–75g intravenously, 2–3 times per week), ascorbate produces pro-oxidant effects selectively within tumour cells via hydrogen peroxide generation, while supporting normal cell antioxidant defence. Multiple peer-reviewed studies and clinical trials—including work from the NIH and the Riordan Clinic—demonstrate reduced inflammatory cytokines, improved quality of life, and enhanced tolerance of chemotherapy. IV vitamin C does not interfere with most chemotherapy protocols when appropriately timed.

Ascorbate 25–75g IV

3× weekly protocol

G6PD screening required

Adjunct to chemo

Mistletoe Therapy (Viscum album / Iscador)

Mistletoe extract, the most widely studied integrative oncology agent in Europe, contains viscotoxins and lectins that stimulate NK cell and T-lymphocyte activity, induce apoptosis in malignant cells, and downregulate tumour-promoting growth factors. More than 100 clinical trials, including a 2020 randomised controlled trial in pancreatic cancer published in Evidence-Based Complementary and Alternative Medicine, demonstrate improved quality of life, immune parameters, and chemotherapy tolerance. Administered by subcutaneous injection, mistletoe is available at Patients Medical as both Iscador and Helixor preparations.

Iscador (subcutaneous)

Helixor preparation

NK cell activation

QoL improvement

Metabolic & Mitochondrial Restoration

The Warburg effect—whereby cancer cells rely heavily on aerobic glycolysis—is exploited through dietary interventions (ketogenic or low-glycaemic-index protocols) and targeted nutraceuticals that support mitochondrial oxidative phosphorylation in normal cells while depriving cancer cells of their preferred fuel. Key agents include CoQ10 (ubiquinol form, 300–600mg/day), alpha-lipoic acid, acetyl-L-carnitine, magnesium glycinate, and B-complex vitamins. Berberine and metformin analogue protocols are sometimes considered to inhibit mTOR and AMPK pathways that cancer cells exploit.

CoQ10 ubiquinol 400mg

Alpha-lipoic acid

Berberine 500mg

Low-glycaemic protocol

Immune System Optimisation & NK Cell Support

Natural killer cell activity is a measurable, modifiable immune parameter with direct relevance to cancer surveillance and recurrence. Our NK cell activation protocol combines beta-1,3/1,6-glucan from Coriolus versicolor (turkey tail) and Ganoderma lucidum (reishi) mushrooms—whose polysaccharopeptide (PSP) and polysaccharide-K (PSK) fractions have the strongest evidence base—with AHCC (Active Hexose Correlated Compound), vitamin D3 optimisation (target 70 ng/mL), and zinc supplementation. NK cell activity assays are used to measure response at 6-week intervals.

Turkey tail PSK/PSP

Reishi beta-glucans

AHCC

Vitamin D3 optimisation

Detoxification & Environmental Toxin Clearance

Carcinogenic environmental toxins—including heavy metals (arsenic, cadmium, lead), persistent organic pollutants (PCBs, dioxins), and endocrine-disrupting chemicals (BPA, phthalates)—are fat-soluble and accumulate in adipose tissue and organ systems, driving ongoing genomic instability. Our detoxification protocols employ modified citrus pectin (MCP) for heavy metal chelation, chlorella and cilantro protocols for bile acid conjugation, glutathione IV infusions to support Phase II hepatic detoxification, and periodic far-infrared sauna therapy to mobilise lipophilic toxins via eccrine sweat.

Modified citrus pectin

Glutathione IV

Far-infrared sauna

Chlorella 3g/day

Neuroendocrine & Stress Regulation

Chronic activation of the sympathetic nervous system and HPA axis—driven by the psychological burden of a cancer diagnosis—directly accelerates tumour progression through beta-adrenergic signalling in cancer cells, which upregulates VEGF (vascular endothelial growth factor) and MMP-9 (matrix metalloproteinase-9), promoting angiogenesis and metastasis. Our protocol combines adaptogenic botanicals (ashwagandha KSM-66, rhodiola rosea), phosphatidylserine (400mg/day) for cortisol buffering, melatonin (10–20mg nightly for anti-proliferative and immune effects), and HeartMath-based biofeedback training for HRV restoration.

Ashwagandha KSM-66

Melatonin 10–20mg

Phosphatidylserine

HRV biofeedback

What to Expect: Treatment Timeline & Monitoring

Weeks 1–4	Comprehensive functional laboratory evaluation. Initial IV vitamin C protocol commenced at lower doses with G6PD screening. Baseline NK cell activity assay. Oncology coordination initiated. Nutritional optimisation and gut restoration begun.
Weeks 5–12	Full IV vitamin C protocol (2–3× weekly during chemotherapy cycles). Mistletoe subcutaneous injection programme commenced. Mitochondrial and detoxification protocols active. Nutritional panel reviewed and deficiencies corrected. Most patients report improved energy, maintained weight, and reduced chemotherapy side effects within 6–8 weeks.
Months 3–6	NK cell activity re-tested at 6-week interval. Tumour markers and oxidative stress panel repeated. Protocol adjusted based on objective response. For patients in remission, transition to long-term terrain maintenance programme.
Months 6+	Quarterly functional panel monitoring. Ongoing immune resilience, anti-inflammatory dietary programme, and microbiome restoration. Annual ctDNA liquid biopsy for early recurrence surveillance. The goal is not just surviving cancer—it is rebuilding the body’s defences so it becomes an inhospitable terrain for recurrence.

Lifestyle Practices for Cancer Recovery & Resilience

The lifestyle recommendations below are not generic wellness advice—they are evidence-backed, mechanistically grounded interventions that directly modulate the biological drivers of cancer progression, treatment tolerance, and recurrence risk.

Structured Aerobic & Resistance Exercise (150 min/week)

Exercise at moderate intensity (60–70% maximum heart rate, 3–5 sessions per week) reduces circulating insulin and IGF-1 by 20–30%, elevates NK cell cytotoxicity, reduces systemic IL-6 and TNF-α, and improves mitochondrial biogenesis via PGC-1α activation. The CHALLENGE trial and meta-analyses of over 10,000 cancer patients confirm that physically active patients have 20–50% lower cancer recurrence rates than sedentary patients. Include 2 sessions of resistance training weekly to preserve lean muscle mass against cancer-associated cachexia.

Sleep Architecture Restoration (7–9 Hours, Circadian-Aligned)

Melatonin—produced during darkness by the pineal gland—has direct anti-proliferative and anti-angiogenic properties in cancer cells, in addition to its role in circadian rhythm maintenance. Disrupted sleep reduces melatonin production, elevates cortisol, impairs DNA repair (which predominantly occurs during deep slow-wave sleep), and suppresses NK cell function. Implement strict sleep hygiene: dark room (blackout curtains), no screens 90 minutes before bed, consistent sleep/wake schedule within 30 minutes, and room temperature 65–67°F.

Daily Parasympathetic Activation (4-7-8 Breathing, 10 min/day)

Chronic sympathetic dominance drives VEGF upregulation and metastasis-promoting MMP-9 activation in cancer cells. Daily practice of structured slow breathing—inhale 4 counts, hold 7 counts, exhale 8 counts, 10 repetitions twice daily—activates the vagal brake, reduces cortisol by 15–23% in clinical studies, and measurably improves HRV. Alternative: body scan meditation using apps such as Insight Timer or 10-Minute Mindfulness, which have specific cancer-pathway research supporting their use.

Safe Sun Exposure for Vitamin D3 Synthesis (15–20 min/day)

Vitamin D3 (calcitriol, the active form) acts as a nuclear transcription factor in over 200 genes involved in apoptosis, angiogenesis inhibition, and immune modulation. Achieving serum 25-OH vitamin D3 levels of 60–80 ng/mL is associated with up to 50% reduction in colorectal cancer mortality and improved prognosis in breast, prostate, and ovarian cancers. Daily exposure of 40% of skin surface to midday sun (10am–2pm) for 15–20 minutes without sunscreen generates approximately 10,000 IU vitamin D3—supplement accordingly if insufficient sun is available.

Reduce Environmental Carcinogen Exposure

Practical, high-impact toxin reduction steps include: replacing non-stick (PTFE/PFOA) cookware with stainless steel or cast iron; filtering tap water with a reverse-osmosis system to remove chlorine, fluoride, lead, and pharmaceuticals; switching to organic produce for the EWG "Dirty Dozen" list; using fragrance-free personal care products to eliminate phthalates and parabens; and testing your home for radon (the second leading cause of lung cancer in the US) with an EPA-certified test kit. These changes measurably reduce urinary phthalate and heavy metal levels within 4–6 weeks.

Social Connection & Meaningful Engagement

Social isolation is a clinically documented immunosuppressant: lonely individuals have measurably lower NK cell activity and higher NF-kB transcriptional activity than socially connected counterparts, independent of other lifestyle factors. Meta-analyses show that strong social ties are associated with a 50% greater likelihood of survival across all cancer types. Practical prescription: maintain at least 3 meaningful in-person social interactions per week, engage with a cancer support group (Gilda's Club, Cancer Care, or hospital-based groups), and consider a cancer-specific integrative health coaching programme.

Diet & Nutrition Guide for Cancer

Diet and nutrition profoundly influence the biological terrain in which cancer lives. Dietary choices regulate insulin and IGF-1 signalling (primary drivers of cancer cell proliferation), systemic inflammation (which promotes tumour survival), gut microbiome composition (which modulates chemotherapy and immunotherapy response), and oestrogen metabolism (critical in hormone-sensitive cancers). The following guide represents an evidence-informed dietary framework—not a rigid prescription—that should be tailored to your cancer type, treatment phase, and individual metabolism with the guidance of your Patients Medical physician.

Single Most Important Dietary Change

Eliminate all added sugars and refined carbohydrates. Cancer cells upregulate glucose transporters (GLUT1, GLUT3) and preferentially consume glucose via aerobic glycolysis (the Warburg effect). High glycaemic-load diets elevate insulin and IGF-1, which directly stimulate cancer cell proliferation through PI3K/AKT/mTOR signalling. Replacing refined carbohydrates with non-starchy vegetables, legumes, and whole grains dramatically reduces this pro-proliferative signal without compromising caloric adequacy.

Eat — Foods That Support Recovery

Cruciferous vegetables (broccoli, cauliflower, kale, Brussels sprouts): Contain sulforaphane and indole-3-carbinol, which induce cancer cell apoptosis, inhibit NF-kB, and support oestrogen 2-hydroxylation pathways.
Wild-caught fatty fish (salmon, sardines, mackerel): EPA and DHA omega-3 fatty acids reduce PGE2-mediated inflammation, compete with arachidonic acid in COX-2 pathways, and improve immune function.
Turmeric / curcumin with black pepper: Curcumin inhibits NF-kB, STAT3, and AP-1 transcription factors; black pepper piperine increases bioavailability by 2,000%.
Berries (blueberries, strawberries, raspberries): Anthocyanins, ellagic acid, and pterostilbene inhibit cancer cell proliferation and angiogenesis while providing high antioxidant activity without interfering with pro-oxidant chemotherapy.
Green tea (Matcha, EGCG): Epigallocatechin gallate (EGCG) inhibits VEGF-mediated angiogenesis, arrests cancer cells in G1 phase, and has demonstrated efficacy in multiple cancer cell lines.
Garlic and alliums (onions, leeks): Allicin and diallyl sulphides inhibit histone deacetylase (HDAC), modulate the cancer epigenome, and have demonstrated antiproliferative activity in colorectal and stomach cancers.
Walnuts and flaxseeds: Rich in alpha-linolenic acid (ALA) and plant lignans (enterolactone, enterodiol), which modulate oestrogen receptor signalling and are associated with reduced breast cancer recurrence in multiple cohort studies.
Fermented foods (kefir, kimchi, sauerkraut, tempeh): Restore Lactobacillus and Bifidobacterium diversity, which is a key predictor of immunotherapy response; short-chain fatty acids from fermentation (butyrate) induce cancer cell differentiation and apoptosis.
Tomatoes (cooked) and lycopene: Lycopene, bioavailable in cooked tomato products, is associated with reduced prostate, lung, and stomach cancer risk; inhibits insulin-like growth factor signalling in prostate cancer cells.

Avoid — Foods That Worsen the Condition

Added sugars and high-fructose corn syrup: Directly elevate insulin and IGF-1, driving PI3K/AKT/mTOR cancer cell proliferation; fructose specifically promotes hepatic de novo lipogenesis, feeding cancer cell membrane synthesis.
Processed and ultra-processed meats (bacon, deli meats, hot dogs): Nitrosamines, heterocyclic amines, and polycyclic aromatic hydrocarbons are classified Group 1 carcinogens by IARC, with strong causal evidence for colorectal cancer.
Refined white flour and high-glycaemic carbohydrates: Spike glucose and insulin rapidly, creating the high-insulin environment that cancer cells exploit for proliferation; replace with whole grains and legumes.
Alcohol: A Group 1 carcinogen via acetaldehyde DNA adduct formation; even moderate intake increases breast, colorectal, liver, and oral cancer risk—no safe threshold has been established for cancer prevention.
Industrially produced seed oils (soybean, corn, sunflower): High omega-6 linoleic acid content elevates arachidonic acid and PGE2, driving COX-2-mediated cancer-promoting inflammation; replace with olive oil and avocado oil.
Charred and flame-grilled meats: Maillard reaction and pyrolysis generate heterocyclic amines (PhIP, MeIQx) and polycyclic aromatic hydrocarbons at high temperatures; these form DNA adducts associated with colorectal and breast cancer.
Conventional non-organic dairy with bovine growth hormone (rBGH): rBGH-treated dairy elevates IGF-1 levels; combined with the oestrogen content of conventional dairy, this represents a meaningful concern particularly in hormone-sensitive cancers.
Artificial sweeteners (aspartame, saccharin): Emerging evidence links some artificial sweeteners to gut microbiome disruption and immunosuppression; saccharin and aspartame are associated with altered chemotherapy metabolism in some studies.

Related & Overlapping Conditions

Cancer rarely exists in biological isolation—it is frequently accompanied by, or predisposed to, a cluster of interrelated conditions that share common upstream drivers including chronic inflammation, immune dysfunction, hormonal imbalance, and metabolic dysregulation.

Anaemia

Cancer-related anaemia (CRA) affects up to 70% of cancer patients, caused by inflammatory cytokine suppression of erythropoietin, direct bone marrow infiltration by tumour cells, or chemotherapy-induced myelosuppression. It is a major driver of cancer-related fatigue and impairs quality of life and treatment tolerance.

Chronic Fatigue

Cancer-related fatigue shares multiple biological mechanisms with chronic fatigue syndrome, including NK cell dysfunction, mitochondrial impairment, HPA axis dysregulation, and elevated pro-inflammatory cytokines—making functional medicine approaches for CFS directly applicable to cancer fatigue management.

Hormonal Imbalance

Dysregulated oestrogen metabolism—particularly through the 4-hydroxylation and 16-hydroxylation pathways that generate genotoxic catechol oestrogens—is a primary driver of breast, endometrial, and ovarian cancer. Testosterone deficiency in men with prostate cancer undergoing androgen deprivation therapy produces a distinct hormonal imbalance syndrome requiring targeted management.

Anxiety & Depression

Over 40% of cancer patients experience clinically significant anxiety and depression—not merely as understandable emotional responses but as neurobiological states driven by inflammatory cytokines crossing the blood-brain barrier and disrupting monoamine neurotransmitter synthesis. These conditions impair immune function and reduce treatment adherence, making their management a clinical priority.

Breast Cancer

Breast cancer is the most common cancer in women and a primary focus of integrative oncology, with robust evidence for the role of oestrogen metabolite profiling, vitamin D3 optimisation, omega-3 supplementation, and exercise in reducing recurrence risk. BRCA1/2 mutation status significantly informs both conventional and integrative prevention strategies.

Immune System Dysregulation

Compromised immune surveillance—whether from chronic stress, nutritional deficiency, gut dysbiosis, or age-related immunosenescence—is a prerequisite for cancer escape from immune elimination. Quantifying and restoring NK cell activity, T-cell diversity, and innate immune signalling is both a cancer prevention and recurrence prevention strategy.

When to See a Doctor About Cancer Warning Signs

One of the most powerful things you can do for your health is to act on symptoms rather than dismiss them. Cancer is consistently more treatable—and in many cases curable—when detected early. The following symptoms warrant prompt medical evaluation, not watchful waiting. If you have experienced any of these for more than three to four weeks without a clear explanation, book an evaluation today.

Seek a Functional Medicine Evaluation If You Notice:

Unintentional weight loss of more than 5% of body weight over 6 months
Persistent, unexplained fatigue not relieved by sleep or rest
A cough, hoarseness, or shortness of breath lasting more than 3 weeks with no respiratory infection
Persistent indigestion, dysphagia (difficulty swallowing), or abdominal pain with no dietary explanation
A mole or skin lesion that has changed in size, shape, colour, or has begun to bleed

A new lump, mass, or swelling anywhere on the body that persists for more than 2–3 weeks
Unusual bleeding from any body orifice—rectal, vaginal, urinary, or haemoptysis
A change in bowel or bladder habits lasting more than 4 weeks, including rectal bleeding
Night sweats and recurrent low-grade fevers in the absence of infection
Family history of BRCA, Lynch syndrome, Li-Fraumeni, or other hereditary cancer syndromes without personal genetic testing

🚨 Seek Emergency Medical Evaluation Immediately If:

Sudden onset of severe headache, confusion, or seizures (potential brain metastasis or primary brain tumour)
Acute spinal cord compression: sudden severe back pain with new leg weakness or bladder/bowel incontinence
Haemoptysis (coughing up significant quantities of blood)
Hypercalcaemia of malignancy: confusion, severe constipation, excessive thirst, and bone pain
Superior vena cava syndrome: severe facial and upper body swelling, neck vein distension, and respiratory distress

What Our Patients Say About Integrative Cancer Support

Individual results vary. These accounts reflect the personal experiences of Patients Medical patients and are shared with their permission. Names have been abbreviated for privacy.

"When I was diagnosed with Stage III breast cancer at 48, I felt like I had no control over what was happening to my body. My oncologist at Memorial Sloan Kettering was wonderful, but there were things I wanted to address—my extreme fatigue, my anxiety, my diet—that were beyond the scope of what she managed. Dr. Gulati and the team at Patients Medical created a protocol that worked around my chemotherapy schedule. By week 8, my energy had measurably improved, I'd maintained my weight when most of my chemo group had lost significant muscle mass, and my NK cell activity had nearly doubled on testing."

"I'm a prostate cancer survivor in my 60s, now three years post-treatment. What brought me to Patients Medical was my concern about recurrence—I had done the surgery, the radiation, the hormonal therapy, but I wanted to know what I could do to make my body as inhospitable to cancer returning as possible. The comprehensive functional evaluation revealed my vitamin D was severely deficient, my NK cell activity was suboptimal, and I had significant oxidative stress markers. With targeted interventions over 12 months, all three normalised, and my PSA has remained undetectable at every follow-up."

"My husband was diagnosed with Stage IV colon cancer and we were absolutely devastated. His oncologist approved our consultation at Patients Medical, and we began the IV vitamin C protocol within three weeks of starting chemotherapy. His side effects from the FOLFOX regimen were noticeably less severe than his oncologist had predicted—he maintained his appetite, had no neuropathy at 3 cycles, and his performance status stayed high enough to continue full-dose treatment. Whether the IV vitamin C was the key factor I can't say with certainty, but it gave us both a sense of agency when we needed it most."

Explore Our Blog For More Insights

Frequently Asked Questions About Cancer

What is cancer and how does it develop in the body?

Cancer is not a single disease but a collection of more than 100 related diseases in which cells in the body begin to grow and divide uncontrollably. Under normal circumstances, cells grow, divide, and die in an orderly process regulated by the DNA instructions within each cell. Cancer begins when one or more of these regulatory mechanisms break down—usually due to accumulated mutations in tumour-suppressor genes (such as TP53 or BRCA1) or proto-oncogenes (such as RAS or MYC).

These mutations can arise from inherited genetic factors, environmental exposures (UV radiation, tobacco carcinogens, asbestos), chronic inflammation, viral infections (HPV, EBV, hepatitis B and C), or errors in DNA replication. Once a cell loses normal growth controls, it divides without stopping, forming a mass of tissue called a tumour. Malignant tumours invade adjacent tissues and, through a process called metastasis, shed cells into the bloodstream or lymphatic system that lodge in and colonise distant organs.

From a functional medicine perspective, cancer development is understood within the broader context of terrain dysfunction—compromised immune surveillance, mitochondrial dysfunction, chronic oxidative stress, and an inflammatory microenvironment all contribute to creating conditions in which cancer cells can survive and flourish. This is why integrative oncology focuses not only on destroying tumour cells but on restoring the biological environment that allowed them to escape immune control in the first place.

How long does integrative cancer treatment take, and what results can I expect?

The timeline for integrative cancer support depends heavily on the cancer type, stage, conventional treatment plan, and the individual patient’s baseline metabolic and immune health. At Patients Medical, integrative support typically runs concurrently with any conventional oncology programme—not as a replacement for it.

In the first four to six weeks, the priority is comprehensive functional assessment and stabilisation: identifying nutrient deficiencies, inflammatory drivers, gut dysbiosis, and metabolic vulnerabilities. During months two through six, active protocols—including intravenous nutrient therapy, immune modulation, and mitochondrial restoration—are implemented and refined based on laboratory monitoring.

Patients in active conventional treatment often report measurably improved tolerance of chemotherapy side effects, better energy, maintained weight, and fewer infections within eight to twelve weeks of starting an integrative programme. For patients in remission, long-term terrain optimisation to reduce recurrence risk is an ongoing process typically monitored every three to six months. Integrative medicine is not a cancer cure—it works to optimise the body’s environment, support conventional treatment efficacy, and improve quality of life throughout the cancer journey.

What tests does Patients Medical use to evaluate cancer patients?

Patients Medical employs a comprehensive panel of functional and conventional laboratory tests that go well beyond standard oncology bloodwork. A full tumour markers panel—including CEA, CA-125, PSA, AFP, and CA 19-9—provides baseline and monitoring data specific to the cancer type. Liquid biopsy testing for circulating tumour DNA (ctDNA) allows detection of genetic mutations and treatment resistance markers without invasive tissue biopsy.

Natural killer (NK) cell activity assays assess the immune system’s current capacity to identify and destroy malignant cells—a critical functional measure that standard oncology panels miss. An NF-kB inflammatory pathway analysis quantifies systemic inflammatory signalling that promotes tumour growth. A comprehensive oxidative stress panel measuring 8-OHdG, glutathione, and superoxide dismutase reveals DNA damage burden and antioxidant reserve.

Nutritional panels assessing vitamins D3, B12, folate, zinc, selenium, magnesium, and omega-3 index identify deficiencies that impair immune function and cellular repair. Depending on cancer type, additional specialised testing such as DUTCH comprehensive hormone metabolite testing, GI-MAP comprehensive stool analysis, and heavy metal urine challenge testing may be ordered.

Can cancer cause extreme fatigue and weight loss even before diagnosis?

Yes—profound, unexplained fatigue and unintentional weight loss are among the most common and clinically significant early warning signs of cancer, and they frequently appear before a formal diagnosis is made. Cancer-related fatigue differs qualitatively from ordinary tiredness: it is a persistent, overwhelming exhaustion that is not proportionate to activity level and is not relieved by rest.

The mechanisms are multiple and interconnected. Tumour cells compete with normal cells for glucose and nutrients, creating a systemic energy deficit. Many cancers release pro-inflammatory cytokines—including IL-6 and TNF-α—that suppress erythropoietin production (causing anaemia) and directly interfere with mitochondrial energy production. Cancer-associated cachexia—a metabolic syndrome characterised by muscle wasting and fat loss—is driven by proteolysis-inducing factor and lipid-mobilising factor secreted by tumour cells. This process is distinct from simple starvation and cannot be reversed by increased caloric intake alone.

Weight loss of more than five percent of body weight over six to twelve months without intentional dieting warrants urgent medical evaluation. If you are experiencing this combination of symptoms—particularly with night sweats, persistent low-grade fever, or enlarged lymph nodes—seek evaluation promptly rather than waiting to see if symptoms resolve.

What is the difference between cancer and a benign tumour?

The fundamental distinction between a malignant (cancerous) tumour and a benign tumour lies in three biological behaviours: invasion, metastasis, and uncontrolled growth. Benign tumours grow in a contained, localised manner, do not invade surrounding tissues, and do not spread to other parts of the body. They are typically enclosed in a fibrous capsule, have well-differentiated cells that closely resemble normal tissue, and are usually slow-growing.

While benign tumours can cause problems through their size and pressure on adjacent structures—a benign brain meningioma can cause serious neurological symptoms—they are not life-threatening in the way malignant tumours are. Malignant tumours invade through the basement membrane into surrounding tissues and shed cells that travel via the bloodstream or lymphatic system to colonise distant organs, forming metastases. It is these metastases that are the primary cause of cancer-related mortality.

It is important to note that some benign tumours can undergo malignant transformation over time—colorectal adenomatous polyps, for instance, can progress to invasive colorectal adenocarcinoma over a period of years, which is precisely why regular colonoscopic surveillance with polyp removal is so effective at preventing colorectal cancer.

How does cancer affect the immune system?

Cancer and the immune system are locked in a complex, dynamic relationship that oncologists call “immunoediting”—a three-phase process of elimination, equilibrium, and escape. In healthy individuals, natural killer (NK) cells, cytotoxic T-lymphocytes (CD8+ T cells), and macrophages continuously survey the body for abnormal cells and destroy them. Many incipient cancers are eliminated at this stage without ever becoming clinically apparent.

However, tumours that survive initial immune elimination enter an equilibrium phase during which the immune system contains but cannot fully eradicate the malignancy. Over time, through genetic mutation and selection pressure, cancer cells develop mechanisms of immune escape: they downregulate MHC class I molecules used by T cells to identify them; they secrete immunosuppressive cytokines such as TGF-β and IL-10; they recruit regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs) that actively suppress anti-tumour immunity; and they upregulate immune checkpoint proteins such as PD-L1, which deliver “don’t kill me” signals to T cells.

This is precisely why modern cancer immunotherapy—including PD-1/PD-L1 checkpoint inhibitors like pembrolizumab and nivolumab—has been so transformative. From a functional medicine perspective, supporting NK cell activity through beta-glucans, mistletoe, vitamin D3, and zinc, reducing systemic inflammation, and restoring gut microbiome diversity all contribute to maintaining the immune surveillance that keeps cancer cells in check.

What supplements and integrative treatments support cancer recovery?

Integrative oncology—the evidence-based combination of conventional cancer treatment with supportive natural therapies—has a growing evidence base. At Patients Medical, all supplement and integrative treatment recommendations are individualised based on cancer type, conventional treatment protocol, and laboratory findings, and are coordinated with the patient’s oncologist to ensure safety and avoid drug interactions.

High-dose intravenous vitamin C (ascorbate at pharmacological doses of 25–75g IV) has been studied in multiple trials as an adjunct to chemotherapy and radiation, with evidence for reduced inflammatory cytokines, improved quality of life, and in some cancer cell lines, pro-oxidant tumouricidal activity. Mistletoe extract (Iscador / Helixor, Viscum album) has robust evidence for improved immune parameters, quality of life, and tolerance of conventional therapy. Vitamin D3 at optimised serum levels of 60–80 ng/mL is associated with improved prognosis in multiple cancer types. Melatonin at therapeutic doses (10–40mg nightly) has documented anti-proliferative, anti-angiogenic, and immune-modulating properties.

Curcumin (from bioavailable formulations like Theracurmin or BCM-95) inhibits NF-kB, a master inflammatory transcription factor that promotes tumour survival. Medicinal mushrooms—particularly Coriolus versicolor (turkey tail, PSK/PSP) and Ganoderma lucidum (reishi)—contain beta-glucan polysaccharides that enhance NK cell and T-cell activity. All supplementation must be carefully screened for interactions with chemotherapy agents—a service Patients Medical provides as a standard part of our integrative oncology consultations.

Ready to Optimise Your Cancer Journey?

At Patients Medical, we believe every person facing a cancer diagnosis deserves a complete biological picture and a personalised plan that works alongside their oncology team—not despite it. Our board-certified integrative physicians combine advanced functional testing with evidence-informed protocols to help you tolerate treatment better, recover faster, and reduce the risk of recurrence.

Call us at (212) 794-8800 · 800 Second Avenue, Suite 900, New York, NY 10017

Begin Your Journey with Patients Medical

Patients Medical specializes in gently helping the patient identify the root cause of their medical issues and then assist them to recover from their problems to help them move forward to good health.

Request your consultation today!

To schedule an in person on Tele-medicine appointment, please call our office at (212) 794-8800 or email us at info@PatientsMedical.com We look forward to hearing from you

Our medical center in New York City.

Patients Medical PC
1148 Fifth Avenue, Suite 1B New York, NY 10128

Make an Appointment

TreatmentsTesting

Please leave this field empty.